Seeing is Believing – The Edwards Mitral & Tricuspid Transcatheter Portfolio
Published: 11 November 2021
-
Views:
5762 -
Likes:
7
-
Views:
5762 -
Likes:
7
-
12m 42sPart 1 Introduction and The Pascal Platform for MR Treatment Didier Tchétché, Sam Dawkins, Philipp Lurz, Peter Lüdike, Sam Dawkins, Nicole Karam, Andreas Rück, Jorg Hausleiter, Michael Böhm
-
12m 18sPart 2 PASCAL MR Live Case – Patient Presentation and Strategy Didier Tchétché, Philipp Lurz, Peter Lüdike
-
9m 39sPart 3 PASCAL Platform – Successful and Durable Treatment of MR Sam Dawkins, Didier Tchétché
-
17m 24sPart 4 PASCAL MR Live Case and Panel Discussion Didier Tchétché, Philipp Lurz, Peter Lüdike, Sam Dawkins, Andreas Rück, Nicole Karam, Jorg Hausleiter, Michael Böhm
-
8m 53sPart 5 The PASCAL Platform for TR Treatment Nicole Karam, Didier Tchétché
-
8m 24sPart 6 PASCAL platform – Safe and Successful Treatment of TR Andreas Rück, Didier Tchétché
-
10m 14sPart 7 Live Case Wrap-up and Panel Discussion Didier Tchétché, Philipp Lurz, Peter Lüdike, Sam Dawkins, Nicole Karam, Andreas Rück, Jorg Hausleiter, Michael Böhm
Overview
This on-demand version of the broadcast "Seeing is Believing – The Edwards Mitral & Tricuspid Transcatheter Portfolio" sees event Chair Didier Tchétché (Clinic Pasteur, Toulouse, FR) joined by an internationally-respected panel, as they explore key elements of the PASCAL platform. Dr Sam Dawkins (John Radcliffe Hospital, UK) explores its practical application for MR, Dr Nicole Karam (European Hospital Georges Pompidou, FR) for TR; whilst Dr Andreas Ruck (Karolinska University Hospital, SE) provides additional insight with a case-based review of its successful, safe application for Tricuspid Valve repair. Prof Jörg Hausleiter (Ludwig-Maximilians Universitat, Munich, DE) looks to the future of TR treatment, with a review of the EVOQUE replacement system. Prof Michael Böhm provides insight from a heart failure perspective throughout the discussions.
The presentations and discussions are set against the back-drop of a live case from the Heart Center Leipzig, under the guidance with Prof Philipp Lurz with Prof Peter Ludike.
Learning objectives
- To discuss the clinical evidence of PASCAL repair system in the treatment of MR and TR
- To learn from case examples how the PASCAL repair system improves outcomes of patients with MR and TR
- To participate in a step-by-step LIVE demonstration of percutaneous mitral leaflet repair with the PASCAL repair system
Audience
- Interventional Cardiologists
- Cardiologists
More from this programme
Part 1
Event Introduction and the PASCAL Platform for MR Treatment
Part 2
PASCAL MR Live Case – Patient Presentation and Strategy
Part 3
PASCAL Platform – Successful and Durable Treatment of MR
Part 4
PASCAL MR Live Case and Panel Discussion
Part 5
The PASCAL Platform for TR Treatment
Part 6
PASCAL Platform – Safe and Successful Treatment of TR
Part 7
Live Case Wrap-up and Panel Discussion
Part 8
The Future of TR Treatment with the Tricuspid Replacement System, and Event Summary
Faculty Biographies
Jorg Hausleiter
Deputy Clinic Director
An interventional cardiologist expert in the field of valvular and coronary heart diseases, Prof Dr Jorg Hausleiter is Professor of Medicine and the Deputy Clinic Director at the Ludwig-Maximilian Universitat in Munich, Germany. He is invested in bringing new and innovative technologies into clinical practice.
Didier Tchétché
Didier Tchétché, (Clinique Pasteur, Toulouse, France) Graduated from the University of Paris V where Dr Tchétché obtained his post-graduate diploma of cardiovascular pathology in 2004. From 2004 to 2005, he completed a 12-month fellowship period in the Hemodynamic and Interventional Cardiology department of Clinique Pasteur in Toulouse and from 2005 to 2007 he was Head Assistant at the intensive care unit of Bichât Hospital in Paris.
In 2008, he joined the interventional cardiovascular group in Clinique Pasteur, Toulouse, and he is currently Head of the Structural programme with an experience of more than 5000 TAVI procedures. His main areas of interest are coronary interventions and valvular heart disease. He has been actively involved in many clinical trials involving new technologies and devices in the field of interventional cardiology.